1453851-73-4

Basic information

• Product Name: Pyrimidine, 4-(2-fluoro-4-pyridinyl)-2-(methylthio)-
• Synonyms: Pyrimidine, 4-(2-fluoro-4-pyridinyl)-2-(methylthio)-
• CAS NO: 1453851-73-4
• Molecular Formula: C₁₀H₈FN₃S
• Molecular Weight: 221.2540232
• Mol File: 1453851-73-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 384.6±27.0 °C(Predicted)
• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• PKA: -2.25±0.31(Predicted)
• CAS DataBase Reference: Pyrimidine, 4-(2-fluoro-4-pyridinyl)-2-(methylthio)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrimidine, 4-(2-fluoro-4-pyridinyl)-2-(methylthio)-(1453851-73-4)
• EPA Substance Registry System: Pyrimidine, 4-(2-fluoro-4-pyridinyl)-2-(methylthio)-(1453851-73-4)

Safety Data

• Hazardous Substances Data: 1453851-73-4(Hazardous Substances Data)

Usage

Description

Pyrimidine, 4-(2-fluoro-4-pyridinyl)-2-(methylthio)is a chemical compound that belongs to the pyrimidine family. It has a molecular formula of C10H8FN3S and a molecular weight of 227.255 g/mol. Pyrimidine, 4-(2-fluoro-4-pyridinyl)-2-(methylthio)features a pyrimidine ring with a fluorine and a methylthio group attached to it, making it a potentially valuable intermediate in the synthesis of pharmaceutical compounds. Its unique structure and properties may have potential applications in drug development and medicinal chemistry.

Uses

Used in Pharmaceutical Industry:
Pyrimidine, 4-(2-fluoro-4-pyridinyl)-2-(methylthio)is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key intermediate in the development of new drugs, contributing to the advancement of medicinal chemistry and drug discovery.

Upstream product

• 959236-97-6 4-bromo-2-methylsulfanylpyrimidine 
• 401815-98-3 2-fluoropyridin-4-ylboronic acid 
• 49844-90-8 4-Chloro-2-methylthiopyrimidine 
• 22282-70-8 2-fluoro-4-iodopyridine 

Downstream Products

• 1453852-36-2 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453847-30-7 (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2( 1H)-one 
• 1453852-38-4 1-((S)-2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-((3S,4S)-3-fluorotetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453847-36-3 1-((S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(((3S,4S)-3-fluorotetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2( 1H)-one 
• 1453847-59-0 (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-57-7 (R)-tert-butyl 2-((S)-(4-chloro-3-fluorophenyl)(4-(2-(methylthio)pyrimidin-4-yl)-2-oxopyridin-1(2H)-yl)methyl)pyrrolidine-1-carboxylate 
• 1453852-86-2 1-benzhydryl-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-88-4 1-benzhydryl-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453847-83-0 1-benzhydryl-4-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-92-0 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-94-2 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-96-4 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethyl)-4-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453847-89-6 (S)-1-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453853-18-3 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 

Relevant articles and documents

Kumada-Corriu Heteroaryl Cross-Coupling for Synthesis of a Pharmaceutical Intermediate: Comparison of Batch Versus Continuous Reaction Modes

Pyridone 1, a key intermediate in the preparation of ERK inhibitor GDC-0994, was synthesized via a cross-coupling/hydrolysis sequence from commercially available starting materials. C-C bond formation was achieved via an efficient palladium catalyzed Kumada-Corriu cross-coupling reaction. However, the 4-pyridylmagnesium halide reagent generated in situ was found to be unstable at the reaction temperature, leading to inconsistent results on scale. In order to address process robustness issues associated with the cross-coupling reaction, we investigated both flow chemistry and a low temperature Kumada-Corriu coupling reaction. Finally, a basic hydrolysis process of 2-fluoropyridine was developed to avoid formation of toxic and corrosive hydrofluoric acid, resulting in a safe and scalable process toward 1.

COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR USE IN TREATMENT OF HYPERPROLIFERATIVE DISEASES

The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

SERINE/THREONINE KINASE INHIBITORS

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.